Freedom Broker analyst Dmitriy Pozdnyakov downgraded Xpel to Hold from Buy with a price target of $45, down from $56. Q1 results came in above consensus and Q2 revenue guidance was broadly in line with expectations, but management's view on the next several quarters "appears cautious," the analyst tells investors.
